Veracyte is expected to post Q3 2026 consensus revenue of $124.82 million and EPS of $0.28, with the current $36.42 share price trading roughly 14% below the $42.50 analyst price target.
Investors are primarily focused on Decipher revenue growth, which remains the company’s most significant engine for both top-line expansion and margin improvement.
Recent performance has been bolstered by increased adoption of the Afirma and Decipher tests, leading to a recent raise in full-year 2026 revenue guidance. Continued progress in the international rollout of these genomic tests is expected to be a major theme during the management call.